Nephron Pharmaceuticals Corporation expanding operations again, adding 380 jobs, $215.8 million investment$215.8 million investment will create 380 new jobs in Lexington County, SC see more
Nephron Pharmaceuticals Corporation (Nephron), a global leader in the production of generic respiratory medications and blow-fill-seal contract manufacturing, today announced plans to expand operations in Lexington County. The company's $215.8 million investment will create 380 new jobs.
A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products, including those used to treat severe respiratory distress symptoms associated with COVID-19.
The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. Nephron fills the needs of patients and health care professionals as they arise nationwide, and recently opened a CLIA-certified diagnostics lab.
Headquartered at 4500 12th Street in West Columbia, Nephron’s expansion will add new offices, a new warehouse and production space at its campus in Saxe-Gotha Industrial Park.
The expansion is expected to be completed by Q1 of 2021. Individuals interested in joining the Nephron team should visit https://www.nephronpharm.com/careers.
The Coordinating Council for Economic Development has approved job development credits related to this project.
“The Nephron family is extraordinarily grateful for the opportunity to grow in South Carolina. Thanks to our partnerships with state and local officials, and the trust they have placed in us, we have been able to provide life-saving medications to patients around the world and establish ourselves as the global leader in what we do. We are proud of these achievements and more, and we know our best days are ahead of us. That is what makes this latest announcement so special.” -Nephron Owner & CEO Lou Kennedy
“We are proud to have Nephron Pharmaceuticals in South Carolina. Since coming here they have become an integral part of the community, and recently have been vital in the fight against COVID-19. This new investment of more than $215 million creating 380 new jobs in Lexington County is a great win for Team South Carolina.” -Gov. Henry McMaster
“Nephron is a longtime steward of South Carolina’s business community, and we congratulate them on their continued growth within our state. Today’s announcement is yet another big win for South Carolina, our people and our burgeoning life sciences sector.” -Secretary of Commerce Bobby Hitt
“We are excited to continue to partner with such an innovative and forward-thinking company like Nephron Pharmaceuticals. We know that Lexington County is a great place to establish and grow a business, and Nephron’s continued success is a testament to good government-business relations.” -Lexington County Council Chairman Scott Whetstone
FIVE FAST FACTS
• Nephron Pharmaceuticals Corporation (Nephron) is expanding operations in Lexington County.
• The $215.8 million investment is projected to create 380 new jobs.
• Nephron is a global leader in the production of generic respiratory medications and blow-fill-seal contract manufacturing.
• Headquartered at 4500 12th Street in West Columbia, S.C.
• Individuals interested in joining the Nephron team should visit https://www.nephronpharm.com/careers.
Spartanburg Regional's Gibbs Cancer Center to open expanded facility see more
With a seven-story, $72 million expansion set to open on March 16, Spartanburg Regional Healthcare System’s Gibbs Cancer Center plans to offer patients treatment beyond traditional chemotherapy and radiation.
At a ribbon-cutting held Thursday, staff unveiled the 191,000-square-foot expansion. The center includes a new physical therapy gym, patient accessible-kitchen, retail shop featuring wigs and prosthesis-fitting services and an on-site outpatient pharmacy. The facility offers radiation, medical and surgical oncology along with cyber knife technologies, centralized lab services, genetic counseling and an integrative medicine center.
“We’re blessed in the Upstate to have a world-class cancer center here that enables patients not to have to travel far,” said Tony Kouskolekas, Pelham Medical Center’s president. “They are able to get first-quality opinions and recommendations on cancer care, and what makes us a little different is that our doctors are committed to what we call multi-disciplinary care. Historically, they have gotten together to discuss someone’s case once someone was diagnosed with cancer. Now, the design of this building will allow them to come together while patients are in the building for multidisciplinary clinics, so that patients can get opinions from multiple providers while they are here for one visit.”
Kouskolekas expects that the center will bring 80 jobs to the area in its first stages, but notes that there is plenty of room to grow as needed.
“To be involved with the planning of this and working with our cancer team has just been another great facet, Kouskolekas said. “Our campus is poised for growth: we have plenty of land and so if we need to do something, we certainly can.”
According to Dr. Michael Starnes, Gibbs Cancer Center’s radiation oncology director, 36 exam rooms have been reserved for the March 16 opening, bringing the center to 75% capacity. Starnes said the center prioritizes clinical research and holistic care alongside traditional treatment measures. The integrative medicine center will allow patients a bridge to recovery through massage and art therapy, tai chi and cooking classes recorded for outpatient survivors to follow.
The new space raises the center’s capacity from less than 10 infusion treatment beds to 40 treatment rooms.
Dr. Heather Allen, a radiology oncologist at Gibbs Cancer Center, noted that the new facility streamlines and strengthens collaborative treatment opportunities spearheaded by oncologists Drs. James Bearden and Julian Josey when they founded the Gibbs Cancer Center 40 years ago.
“They were ahead of the game. This is the model that works, but it wasn’t in place 40 years ago. It was their vision to take a new paradigm shift in cancer treatment and bring it home to the local area,” Allen said.
MUSC Shawn Jenkins Children’s Hospital and Pearl Tourville Women’s Pavilion open see more
The long-awaited MUSC Shawn Jenkins Children’s Hospital and Pearl Tourville Women’s Pavilion opened Saturday, bringing a dedicated space for women’s and children’s health care to the Lowcountry.
In just under 12 hours, Medical University of South Carolina staff and partners transported almost 200 patients from the former MUSC Children’s Hospital on Ashley Avenue to the new building on the corner of Courtenay Drive and Calhoun Street.
“We saw an incredible amount of teamwork and a very professional approach to the whole thing, but also just a whole lot of joy,” said Mark Scheurer, MUSC Children’s Hospital chief medical officer and project leader. “It was really fun just watching the little things happen that you talked about in the planning period when they were just hypothetical.”
The 11-story hospital includes the state’s only level-one pediatric trauma and burn unit and the state’s largest level-four NICU.
Starting with patients in the neonatal intensive care unit, teams simultaneously transported patients along four routes with the use of 36 ambulances, Scheurer said.
The 11-story, 625,000-square-foot hospital includes a 20% increase in capacity. It has the state’s only level-one pediatric trauma and burn unit and the state’s largest level-four NICU. There also is an advanced fetal care center and a dedicated elevator for transporting mothers in labor from the hospital’s entrance directly to the fourth-floor maternity pavilion.
“This new hospital is so important for the community because it will offer a different experience for women and children and their families because they (the team) will be able to deliver care using new technology,” said Carolyn Donohue, MUSC’s executive director of nursing for children’s and women’s health. “It also involves our patients to be able to use that technology to improve their ability to communicate with the health care team and their family during the acute care of their hospitalization.”
This $389 million project was expected to open in October and then December. Neither opening took place delayed after setbacks from Hurricane Dorian and because the hospital didn’t pass safety and regulatory inspections.
The hospital began its operating room and outpatient services Monday. Staff members will continue to move in any remaining supplies and equipment and to monitor operations to make sure they work as smoothly as planned.
Life sciences in South Carolina is big business -- and getting bigger by the day. Read why... see more
In this article published simultaneously in Charleston Business Magazine, Columbia Business Magazine and Greenville Business Magazine, SCBIO CEO Sam Konduros paints a picture of the diversity of the rapidly-growing life sciences industry, and why the future is exceedingly bright -- and getting brighter -- as the $11.4 billion industry soars to new heights across South Carolina.
Life sciences in South Carolina spans a diverse spectrum—from major pharmaceutical companies to globally known medical device companies.
It encompasses start-ups and early stage innovation companies and embraces prestigious research universities and acclaimed health care systems employing some of America’s finest minds. It includes research and medical labs, bioscience-related distribution, even Bio-Ag tied to the state’s historical agricultural segment. Click to read complete article...
South Carolina’s $90-million research pipeline creates jobs and improves healthcare, researchers sayResearch pipeline adds jobs and improves healthcare in South Carolina see more
The $41.8 million that has flowed into Clemson University for three separate research centers could be the beginning of a larger enterprise that brings South Carolina new business, improved patient care and lower healthcare costs.
But success will hinge on how well some of the state’s largest institutions can work together, researchers said.
The funding comes from a National Institutes of Health program that is aimed at helping South Carolina, 22 other states and Puerto Rico establish Centers of Biomedical Research Excellence. Each has a specific research theme and can receive as much as $30 million distributed in three phases over 15 years. SC BioCRAFT, launched in 2009, has received two phases of funding totaling $20.3 million. Clemson officials announced Oct. 18 that SC-TRIMH received $11 million in its first phase of funding. EPIC started in 2015 with $10.5 million.
Those centers could be just the start of a continuous funding stream– a big one that transforms the South Carolina healthcare industry. Clemson officials are preparing to apply for a fourth center and have set a goal of continuously maintaining three centers. The plan would create a pipeline worth up to $90 million at any given time constantly flowing into South Carolina for biomedical research.
Clemson bioengineers lead two of the centers, SC BioCRAFT and SC-TRIMH. They said they rely on clinicians from Greenville Health System and the Medical University of South Carolina to guide their research, ensuring it remains relevant to what happens in real-world hospitals and clinics.
“Team effort is what is required,” said Naren Vyavahare, the director of SC BioCRAFT. “A lot of institutions are required for these big grants.”
One of the gems of the centers is that junior faculty members are mentored so that they can compete for their own federal funding. SC BioCRAFT is credited with mentoring 23 faculty members and generating $35 million in addition to the $20.3 million that funds the center itself. The center is also bearing fruit off campus. Research done at SC BioCRAFT has led to 16 patents, four spin-off companies and better care for patients suffering from ailments ranging from diabetes to traumatic brain injury.
The success of SC BioCRAFT could be a harbinger for the newest center, SC-TRIMH, which is led by Hai Yao, theErnest R. Norville Endowed Chair in Biomedical Engineering at Clemson.
A key part of SC-TRIMH’s mission is developing virtual human trials that would allow researchers to test new devices with computational models before trying them on humans. The idea is to close the gap between animal and human trials, allowing new devices to move from the lab to patients’ bedsides more quickly and less expensively. It’s an approach that has been used for drugs, but SC-TRIMH will be the first to try to apply it to medical devices, a step that could attract device manufacturers to the state, Yao said.
“The companies are going to come to us,” Yao said. “Why? Because we have the technology, and we have clinical partners here. So, we can test their products– not just test their products but use our technology to totally redesign their products.”
Initial research could apply to bad discs in the back, hip replacements and disorders of the temporomandibular joint, Yao said.
Martine LaBerge, chair of the Department of Bioengineering at Clemson, said SC-TRIMH could improve patient care for South Carolinians by staking a claim as a national leader in musculoskeletal health, the center’s primary focus.
“If we’re the leader, why would a patient need to fly to another state for treatment?” she asked. “We’ll become the leading health provider. Patients from other states may have to fly to South Carolina. This is our goal, and collaboration among institutions will be crucial to making it happen.”
Tanju Karanfil, vice president for research at Clemson, said officials are preparing to apply for a fourth center but will have to wait until 2020, because NIH rules limit each institution to three centers in the first two phases. He said that he is hopeful that SC BioCRAFT will receive Phase III funding.
“This is excellent for a university without a medical school,” Karanfil said. “Of course, with all credit, we are working with GHS, MUSC and USC. Their clinical expertise is indispensable.”
Vyavahare, the Hunter Endowed Chair at Clemson, took the lead in organizing the university’s first center, SC BioCRAFT, starting in 2006. The first proposal was rejected, and then a federal funding shortfall in 2008 put the program on hold for a year, he said. SC BioCRAFT received its first $10 million in 2009, and funding was renewed for the second phase five years later. Vyvahare said he is most proud of the center’s junior faculty.
SC BioCRAFT provided mentors who helped guide them through the research funding process, he said. The center also helped pay for new research equipment that is crucial to generating the data needed for a successful research proposal, Vyavahare said.
“It’s a good way to start your career quickly,” Vyavahare said. “A lot of people started getting good data, and everybody started getting funding.”
SC BioCRAFT is an acronym for the South Carolina Bioengineering Center for Regeneration and Formation of Tissues. SC-TRIMH stands for the South Carolina Center for Translational Research Improving Musculoskeletal Health. EPIC stands for Eukaryotic Pathogens Innovation Center.
Researchers said one of the key ingredients in the success of SC BioCRAFT and SC-TRIMH is Clemson’s deep integration with GHS and MUSC.
Both centers are based at the Clemson University Biomedical Engineering Innovation Campus, or CUBEInC, which is on the GHS Patewood Medical Campus in Greenville. Research is also conducted at MUSC, where Clemson has space in the medical university’s Bioengineering Building.
The value of collaboration was a consistent theme when researchers from the three institutions gathered to announce the creation of SC-TRIMH.
Scott Sasser, chief clinical officer for the GHS western region, said that Clemson was the health system’s primary research partner.
“That was by design, and it is unique,” he said. “We are so thankful for your investment in the medical school. The successful medical education of every student who walks through our doors is inextricably tied to your commitment to research that this project exemplifies.
“The novel methodology that will be used in this program will lead to new innovations and new devices that will not only change health outcomes but will help us all address the rising cost of healthcare in this country.”
Michael Kern, a professor in the Department of Regenerative Medicine and Cell Biology at MUSC, said what excites him most about SC-TRIMH is the chance to continue working with Yao.
“My research and Hai’s research before the COBRE grant have dovetailed nicely,” he said, using the acronym for the NIH funding program. “We’ve worked quite closely together for the previous 12 years. With the COBRE, we will be able to continue our work together to benefit young investigators and help them mature in their science.”
Kathleen Brady, associate provost for clinical and translational science at MUSC, said collaboration is part of a growing trend in research because it leads to success.
“When groups get together, studying a similar problem, you’re much more likely to come up with innovative solutions,” she said. “They are usually innovative solutions that neither group could have come up with on their own. SC-TRIMH is a perfect example of that– people with very different expertise coming together to do something unique and innovative.”
Spence Taylor, president of GHS, said in a written statement that working together can lead to significantly improved health care and health outcomes in South Carolina and the nation.
“These innovative partnerships between Clemson faculty and GHS clinicians allow us to solve clinical challenges by leveraging medical insights with the extraordinary research depth of Clemson,” he said. “What we do today can pave the way for transformational improvements to health care for generations to come.”
Vincent Pellegrini, chair of the Department of Orthopedics at MUSC, said much of the SC-TRIMH research will focus on musculoskeletal conditions that result from normal aging, including arthritis at the base of the thumb, hip replacement prostheses and tendon degeneration.
“The really exciting thing about the COBRE is that it juxtaposes the engineering, science and clinical medicine with the appropriate individuals in those disciplines on the same campus under the same roof to come up with real, clinically relevant devices and products that benefit patients,” he said.
Michael Kissenberth, a GHS orthopedic surgeon, said the collaboration will allow the institutions to complement each other
“We at GHS will be able to advise on the clinical needs that Clemson can then use to develop the technology that improves health outcomes,” he said. “In some cases, the technology may exist, and we can help show how it can be applied.”
Kyle Jeray, a GHS orthopedic surgeon, said SC-TRIMH will strengthen the collaborative spirit in South Carolina’s research community.
“Through SC-TRIMH, we will enhance the research infrastructure at Clemson and GHS by developing essential core facilities, fostering research collaborations and increasing scientific expertise of junior and senior faculty members,” he said.
Windsor Sherrill, associate vice president for Health Research at Clemson and chief science officer at GHS, said she wanted to recognize Tommy Gallien, the manager/coordinator for SC-TRIMH. She also wanted to acknowledge the Clemson University School of Health Research, or CUSHR.
“CUSHR is the interdisciplinary health research entity at Clemson that connects health researchers across colleges and departments with clinical researchers at health care systems such as GHS and MUSC,” she said. “The junior investigators for the SC-TRIMH initiative are from several different departments, ensuring that we have multidisciplinary focus to solve complex health care problems. The big challenges in health care do not fit neatly within one discipline or even in one university. SC-TRIMH is the kind of program we envision with CUSHR– one that leverages talents across Clemson health research faculty with the input of clinicians research at our partner institutions.”
Anand Gramopadhye, dean of the College of Engineering, Computing and Applied Sciences, congratulated Yao and his team on the SC-TRIMH grant.
“Through this grant, Dr. Yao and his team from Clemson, GHS and MUSC are strengthening the biomedical research capacity for South Carolina,” he said. “The award is a testament to the scholarship that Dr. Yao brings to Clemson and the power of collaboration to achieve the most innovative results.”
MUSC expands footprint with acquisition of four community hospitals in South Carolina. see more
The Medical University of South Carolina board of trustees voted Monday night to acquire four community hospitals in north-central South Carolina and the Pee Dee.
Community Health Systems, a publicly traded hospital company based in Franklin, Tenn., plans to sell the hospitals, plus their associated physician clinics and outpatient services, to MUSC:
- Chester Regional Medical Center, an 82-bed licensed facility.
- Carolinas Hospital System in Florence, a 396-bed regional, acute-care facility.
- Springs Memorial Hospital in Lancaster, a 225-bed all private-room facility.
- Carolinas Hospital System – Marion in Mullins, a 124-bed acute-care facility providing a variety of inpatient and outpatient services, as well as a 92-bed nursing center.
This is the first time MUSC has agreed to acquire other hospitals. Once the acquisition is complete, MUSC will employ more than 16,400 people throughout the state.
The Medical University of South Carolina's board of trustees voted Monday to acquire four community hospitals in the first quarter, pending approval by the State Fiscal Accountability Authority. (Photo/File)
“The additions will increase the size and scale of the MUSC Health network, and in today’s environment, larger, more efficient health care systems can deliver greater value to patients and have a positive impact on population health,” board Chairman Charles Schulze said in a news release. The MUSC board’s unanimous vote to approve the acquisition came after two hours of discussion in executive session during a special called meeting. Once called to order, the meeting almost immediately went into executive session, which is closed to the public, and the subsequent public vote took less than two minutes.
The transaction is expected to close in the first quarter, according to a news release from Community Health Systems. MUSC spokeswoman Heather Woolwine said in an email that no dollar figure for the acquisition was available yet. The transaction must still be approved by the State Fiscal Accountability Authority, according to the board’s resolution.
“As the state’s leading academic health center, we must be prepared for the future,” MUSC President Dr. David Cole said in a news release. “MUSC is committed to providing the best health care possible for our communities and state through strategic partnerships and our emerging MUSC Health network.”
MUSC receives grant for expansion of telehealth program see more
The Medical University of South Carolina (MUSC) palliative care program has received a $1,278,000 grant from The Duke Endowment to create a statewide, palliative care telehealth program.
Providing end of life and comfort care to those in need, especially for the state’s most vulnerable and rural populations, is the primary aim of the new effort. Program leadership expects not only an improvement to accessibility for this kind of care, but also potential cost savings to individual patients and the system as a whole. Click for full details.
South Carolina life sciences gets another huge boost with BD's $150 million investment in Sumter see more
Medical technology company creating 125 new jobs
COLUMBIA, S.C. - BD (Becton, Dickinson and Company), a leading global medical technology company, today announced a $150 million investment in its existing Sumter County manufacturing facility. The company is projected to create an additional 125 new jobs over the next several years.
Employing more than 65,000 associates worldwide, BD is one of the world's largest medical technology companies and supports health care providers in more than 190 countries. BD's Sumter County facility has been in operation since 1970, manufacturing blood collection devices that are critical to the health care industry.
Located at 1575 Airport Road in Sumter, S.C., BD's Sumter facility is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.
The Coordinating Council for Economic Development has approved job development credits related to this project, as well as a $600,000 Set Aside grant to assist with the costs of road work and site preparation.
"For nearly 50 years, BD's Sumter facility has consistently delivered superior quality products, vital for our customers and their patients, through a talented and engaged workforce. We would like to thank TheLINK economic development alliance, Sumter Economic Development, the City of Sumter, Sumter County and the S.C. Department of Commerce for their continued support of BD and our employees as we continue to invest in the facility. We look forward to the ongoing success of our BD Sumter manufacturing team as they continue to advance the world of health." -BD Executive Vice President of Global Operations and Chief Supply Chain Officer Jim Borzi
"After opening in our state more than 40 years ago, we're thrilled that BD continues to grow and succeed here. This announcement once again demonstrates that South Carolina is a place where medical technology companies want to do business, and we welcome this new $150 million investment." -Gov. Henry McMaster
"Not only does our state excel in advanced manufacturing, we're also increasingly a top choice for companies in the life sciences sector. BD has been a strong member of Team South Carolina for decades, and we congratulate them on their ongoing success." -Secretary of Commerce Bobby Hitt
"BD has been a leading employer in this county since opening its doors in 1970. We are grateful for their continued investment in our community and our people." -Sumter County Council Chairman James McCain
"We have long-enjoyed BD as a key component in the fabric of our industrial portfolio. This investment demonstrates their trust in our leadership, their commitment to the success of their business and their belief in our ability to regenerate the talent needed to produce the quality of goods for which BD is known." -Sumter Economic Development Chairman Greg Thompson
FIVE FAST FACTS
- BD is investing in its existing Sumter County manufacturing facility.
- $150 million investment to create 125 new jobs.
- Employing more than 65,000 associates worldwide, BD is one of the largest medical technology companies in the world and supports health care providers in more than 190 countries.
- Located at 1575 Airport Road in Sumter, S.C., BD's facility manufactures blood collection devices for the health care industry.
BD is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit www.bd.com.